Participants 106 134 6
patients with liver failure]
Participants 290 382 5
subjects with liver failure, and to evaluate the safety of different anticoagulation methods
Participants 446 729 9
According to anticoagulation Methods , 174 MARS treatment sessions for 146 patients with liver failure and prothrombin time activity percentage (PTA) â‰¤ 40% were randomly divided into 2 groups: 92 MARS treatment sessions in the heparin-free group and 82 in the low-dose heparin grou
